MedTrace Logo

Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning

NCT02308332 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2017-10-27

No results posted yet for this study

Summary

This study will evaluate the effects of switching Atripla to Eviplera on neurocognition measured by neuropsychological testing and functional MRI

Conditions

  • Neurocognitive Decline
  • HIV Associated Neurocognitive Disorder

Interventions

DRUG

Eviplera

switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)

Sponsors & Collaborators

Principal Investigators

  • Joop Arends, MD PhD · UMC Utrecht

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02308332 on ClinicalTrials.gov